{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"800"},{"groupId":"OG001","value":"800"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"description":"To determine the recommended Phase 2 dose of NM21-1480 for Part B of the study","groups":[{"description":"Part A Dose Level 7 NM21-1480-Q2W 800mg","id":"OG000","title":"Part A Dose Level 7 NM21-1480-Q2W 800mg"},{"description":"Part A2 NM21-1480-Q2W 1400mg","id":"OG001","title":"Part A2 NM21-1480-Q2W 1400mg"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"From baseline to up to 12 weeks post last dose, up to 48 weeks.","title":"Determination of Phase 2 Dose of NM21-1480","type":"PRIMARY","unitOfMeasure":"mg"}